BIOMAT Database Logo BIOMAT Database Logo

Effect of adjuvant reserpine treatment on catecholamine metabolism in schizophrenic patients under long-term neuroleptic treatment. 1988

G Bagdy, and A Perenyi, and E Frecska, and A Seregi, and M I Fekete, and L Tothfalusi, and K Magyar, and A Bela, and M Arato
National Institute for Nervous and Mental Diseases, Budapest, Hungary.

The clinical and biochemical effects of adjuvant reserpine treatment were investigated in 12 chronic schizophrenic patients on long-term neuroleptic medication. The global severity of the symptoms using the Brief Psychiatric Rating Scale did not change significantly in the whole group, however, a moderate decrease in positive symptoms (factors though disturbance, activation and hostile-suspiciousness) was observed for 5 patients. Cerebrospinal fluid (CSF) noradrenaline levels showed a consistent decrease, but other biochemical parameters (CSF dopamine metabolites, platelet MAO and serum dopamine-beta-hydroxylase activities) did not change significantly. The changes of clinical symptoms and biochemical parameters did not show any correlation.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008995 Monoamine Oxidase An enzyme that catalyzes the oxidative deamination of naturally occurring monoamines. It is a flavin-containing enzyme that is localized in mitochondrial membranes, whether in nerve terminals, the liver, or other organs. Monoamine oxidase is important in regulating the metabolic degradation of catecholamines and serotonin in neural or target tissues. Hepatic monoamine oxidase has a crucial defensive role in inactivating circulating monoamines or those, such as tyramine, that originate in the gut and are absorbed into the portal circulation. (From Goodman and Gilman's, The Pharmacological Basis of Therapeutics, 8th ed, p415) EC 1.4.3.4. Amine Oxidase (Flavin-Containing),MAO,MAO-A,MAO-B,Monoamine Oxidase A,Monoamine Oxidase B,Type A Monoamine Oxidase,Type B Monoamine Oxidase,Tyramine Oxidase,MAO A,MAO B,Oxidase, Monoamine,Oxidase, Tyramine
D011388 Prolactin A lactogenic hormone secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). It is a polypeptide of approximately 23 kD. Besides its major action on lactation, in some species prolactin exerts effects on reproduction, maternal behavior, fat metabolism, immunomodulation and osmoregulation. Prolactin receptors are present in the mammary gland, hypothalamus, liver, ovary, testis, and prostate. Lactogenic Hormone, Pituitary,Mammotropic Hormone, Pituitary,Mammotropin,PRL (Prolactin),Hormone, Pituitary Lactogenic,Hormone, Pituitary Mammotropic,Pituitary Lactogenic Hormone,Pituitary Mammotropic Hormone
D012110 Reserpine An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use. Raunervil,Raupasil,Rausedil,Rausedyl,Serpasil,Serpivite,V-Serp,V Serp
D002395 Catecholamines A general class of ortho-dihydroxyphenylalkylamines derived from TYROSINE. Catecholamine,Sympathin,Sympathins
D004299 Dopamine beta-Hydroxylase Dopamine beta-Monooxygenase,Dopamine beta Hydroxylase,Dopamine beta Monooxygenase,beta-Hydroxylase, Dopamine,beta-Monooxygenase, Dopamine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000277 Adjuvants, Pharmaceutic Agents that aid or increase the action of the principle drug (DRUG SYNERGISM) or that affect the absorption, mechanism of action, metabolism, or excretion of the primary drug (PHARMACOKINETICS) in such a way as to enhance its effects. Adjuvant, Pharmaceutic,Adjuvant, Pharmaceutical,Adjuvants, Pharmaceutical,Pharmaceutic Adjuvant,Pharmaceutic Adjuvants,Pharmaceutical Adjuvant,Pharmaceutical Adjuvants
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

G Bagdy, and A Perenyi, and E Frecska, and A Seregi, and M I Fekete, and L Tothfalusi, and K Magyar, and A Bela, and M Arato
Calcium metabolism in schizophrenic patients on long-term neuroleptic therapy.
January 1980, Neuropsychobiology,
G Bagdy, and A Perenyi, and E Frecska, and A Seregi, and M I Fekete, and L Tothfalusi, and K Magyar, and A Bela, and M Arato
[Clinical-chemical studies in schizophrenic out-patients under neuroleptic long-term treatment with particular consideration of the hepatic metabolism (author's transl)].
January 1977, Pharmakopsychiatrie, Neuro-Psychopharmakologie,
G Bagdy, and A Perenyi, and E Frecska, and A Seregi, and M I Fekete, and L Tothfalusi, and K Magyar, and A Bela, and M Arato
Antipsychotic drug action in schizophrenic patients: effect on cortical dopamine metabolism after long-term treatment.
September 1979, Science (New York, N.Y.),
G Bagdy, and A Perenyi, and E Frecska, and A Seregi, and M I Fekete, and L Tothfalusi, and K Magyar, and A Bela, and M Arato
[Long-term treatment of schizophrenic psychoses using retard-neuroleptic preparations].
April 1972, Die Medizinische Welt,
G Bagdy, and A Perenyi, and E Frecska, and A Seregi, and M I Fekete, and L Tothfalusi, and K Magyar, and A Bela, and M Arato
[Psychomotor performance of schizophrenic patients and long-term neuroleptic therapy].
January 1983, Psychiatria clinica,
G Bagdy, and A Perenyi, and E Frecska, and A Seregi, and M I Fekete, and L Tothfalusi, and K Magyar, and A Bela, and M Arato
Evolution of neuroleptic-induced extrapyramidal syndromes under long-term neuroleptic treatment.
March 2008, Schizophrenia research,
G Bagdy, and A Perenyi, and E Frecska, and A Seregi, and M I Fekete, and L Tothfalusi, and K Magyar, and A Bela, and M Arato
Long-term neuroleptic treatment of chronic schizophrenic patients: clinical and biochemical effects of withdrawal.
January 1981, Psychopharmacology,
G Bagdy, and A Perenyi, and E Frecska, and A Seregi, and M I Fekete, and L Tothfalusi, and K Magyar, and A Bela, and M Arato
Long term effect of lithium on brain regional catecholamine metabolism.
May 1990, Indian journal of experimental biology,
G Bagdy, and A Perenyi, and E Frecska, and A Seregi, and M I Fekete, and L Tothfalusi, and K Magyar, and A Bela, and M Arato
Endocrinological changes in patients with sexual dysfunction under long-term neuroleptic treatment.
November 1979, Pharmakopsychiatrie, Neuro-Psychopharmakologie,
G Bagdy, and A Perenyi, and E Frecska, and A Seregi, and M I Fekete, and L Tothfalusi, and K Magyar, and A Bela, and M Arato
Autonomous prolactin secretion in schizophrenic male on long-term neuroleptic therapy.
July 1981, Lancet (London, England),
Copied contents to your clipboard!